Company / Free Cash Flow
Vertex Pharmaceuticals Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$3.2B
FY2025
5-year range
-$790.3M / $3.9B
FY2021-FY2025
Trend
+504.1%
vs FY2024
Sector context
#9 of 194
Health Care
What the data says
Free Cash Flow changed +504% YoY in FY2025, a notable deviation from the 9-year average annual change of +101%.
Based on SEC 10-K filings.
$3.2B in FY2025 with a 5-year CAGR of +1.3%. Top quartile in the Health Care sector.
Declined from $3.3B to $3.2B over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -6.6%
- 5-Year CAGR
- +1.3%
- 10-Year CAGR
- -
Sector benchmark
Top 5% in Health CareTop 5% of 194This company $3.2B Sector average $470.6M
▼
+578.7% above sector average
Key checks
Key Insights
- 5-year CAGR of +1.3%, indicating consistent growth.
- In FY2025, free cash flow increased 504.1% year-over-year.
- Ranks #9 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2022.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.2B | +504.1% |
| FY2024 | -$790.3M | -123.7% |
| FY2023 | $3.3B | -15.0% |
| FY2022 | $3.9B | +63.0% |
| FY2021 | $2.4B | -19.5% |
| FY2020 | $3.0B | +100.4% |
| FY2019 | $1.5B | +27.2% |
| FY2018 | $1.2B | +57.6% |
| FY2017 | $745.5M | +315.2% |
| FY2016 | $179.5M | +143.7% |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026